Mounjaro Active Ingredient and Drug Class
Mounjaro contains tirzepatide as its sole active pharmaceutical ingredient. Tirzepatide is a synthetic peptide that acts as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. The molecule is designed to mimic two natural incretin hormones involved in blood sugar and appetite regulation. Eli Lilly and Company developed tirzepatide, and the U.S. Food and Drug Administration approved Mounjaro for adults with type 2 diabetes in May 2022. The approval was based on clinical trials showing reductions in glycated hemoglobin and body weight compared with placebo. For more on the regulatory background, see the FDA approval information on Eli Lilly's official site Eli Lilly official site.
Tirzepatide is a 39-amino-acid linear peptide with a C18 fatty diacid attached via a glutamic acid spacer and a C20 diacid ester linker. This structure increases albumin binding, which slows kidney clearance and extends the half-life. The molecule is not derived from human or animal tissue; it is manufactured through solid-phase peptide synthesis. Mounjaro is supplied as a sterile, preservative-free, aqueous solution for subcutaneous injection in single-dose prefilled pens and multi-dose vials. Each pen delivers a fixed volume of clear to slightly opalescent, colorless to slightly yellow solution.
Mounjaro Formulation, Excipients, and Delivery System
Inactive Ingredients and Stabilizers
The formulation includes several excipients that maintain stability, tonicity, and pH. Key inactive components are citric acid monohydrate, sodium citrate dihydrate, polysorbate 80, and water for injection. Citric acid and sodium citrate act as a buffer system to keep the solution within a target pH range that supports peptide stability. Polysorbate 80 functions as a surfactant to reduce protein adsorption to the container and syringe surfaces and to help maintain a clear solution. The final product does not contain preservatives, such as phenol or benzyl alcohol, which is why Mounjaro pens are designed for single-patient use and must be stored properly.
Each prefilled pen contains 0.75 mL or 1.5 mL of solution, delivering doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide depending on the pen type and injection step. The pen uses a hidden-needle system with a dial-based dose selector to improve ease of use and dosing accuracy. The device is made of polycarbonate and stainless steel components, with a silicone-based lubricant on the plunger rod to ensure smooth delivery. Mounjaro must be stored in a refrigerator at 2 degrees C to 8 degrees C before first use and can be kept at controlled room temperature up to 30 degrees C for a limited period after initial removal from the refrigerator.
Manufacturing, Supply Chain, and Commercial Status
Production and Global Supply
Eli Lilly manufactures Mounjaro at dedicated peptide synthesis and fill-finish facilities, with supply chains spanning multiple continents to support global demand. The company has invested heavily in expanding tirzepatide production capacity to address shortages and to support the growing number of indications. In the United States, Mounjaro is one of the highest-revenue pharmaceutical products for Eli Lilly, with sales driven by both the diabetes and weight management markets. The manufacturer also produces a companion lower-dose formulation for weight management under a separate brand name, which uses the same active ingredient but different labeling and dosing instructions.
Mounjaro is classified as a prescription-only biologic product, and its distribution is managed